193979-48-5

Upstream product

• 1072-98-6 5-chloro-2-pyridylamine 
• 1381932-40-6 C₁₄H₁₄ClNO₆ 
• 706-07-0 1-chloro-4-(2-nitrovinyl)benzene 
• 99-91-2 para-chloroacetophenone 
• 89781-40-8 C₁₂H₁₁ClO₃ 
• 695-34-1 2-Amino-4-methylpyridine 
• 104-88-1 4-chlorobenzaldehyde 
• 623-47-2 propynoic acid ethyl ester 
• 64-17-5 ethanol 
• 82626-72-0 2-(6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)acetonitrile 
• 329937-06-6 C₁₂H₈Cl₂N₂ 
• 53503-49-4 ethyl 4-(4-chlorophenyl)-4-oxobutanoate 
• 35158-46-4 3-bromo-4-(4-chloro-phenyl)-4-oxo-butyric acid ethyl ester 
• 71-36-3 butan-1-ol 

Downstream Products

• 82626-74-2 2-(6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)acetic acid 
• 82625-99-8 2-(6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethylacetamide 

Relevant academic research and scientific papers

Rhodium(II)-Catalyzed Regioselective C3-Alkylation of 2-Arylimidazo[1,2-a]pyridines with Aryl Diazoesters

A regioselective C3-alkylation based on the reaction of 2-arylimidazo[1,2-a]pyridines with a wide range of aryl α-diazoesters in the presence of a Rh(II) catalyst in dichloroethane at room temperature was developed. This method could be applied in the synthesis of benzoimidazoquinolizinone and cycloheptaimidazopyridinone, which are novel heterocyclic scaffolds. (Figure presented.).

COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT

The present invention features novel peripherally-restricted non-benzodiazipene analogs with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with A

3-ALKYLATED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AND ITS PREPARATION METHOD

Of a typic a.a typa/aβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbeta.beteq.a a.sub .beteq.a.sub βbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβbetaβ

Magnetic Cu0@HAP@γ-Fe2O3 nanoparticles: An efficient catalyst for one-pot three-component reaction for the synthesis of imidazo[1,2-a]pyridines

Cu(0) incorporated magnetic hydroxyapatite nanoparticles (Cu0@HAP@γ-Fe2O3 NPs) was conveniently synthesized via the ion exchange reaction, oxidation, and reduction steps. The structure and composition of the nanohybrid wer

Visible-Light-Induced Regioselective Cyanomethylation of Imidazopyridines and Its Application in Drug Synthesis

3-Cyanomethylated imidazopyridines were synthesized via a visible light-promoted reaction of imidazopyridines with bromoacetonitrile or iodoacetonitrile catalyzed by fac-Ir(ppy)3 under mild conditions. For the substrates with various substituents on benzene or pyridine ring, the reaction proceeded smoothly to give the corresponding products in moderate to good yields. The synthetic utility of this visible-light-induced reaction has been illustrated in the efficient synthesis of zolpidem and alpidem.

Copper(II)-Mediated Aerobic Synthesis of Imidazo[1,2-a]pyridines via Cascade Aminomethylation/Cycloisomerization of Alkynes

A single copper(II)-catalyzed three-component cascade aminomethylation/cycloisomerization of propiolates to form imidazo[1,2-a]pyridines was explored. A straightforward method was developed for the practical synthesis of functionalized imidazo[1,2-a]pyridines from benzaldehydes, 2-aminopyridines, and propiolate derivatives catalyzed by Cu(OAc)2 hydrate in the presence of air. The protocol is marked by excellent yields, functional group tolerance, and, above all, adaptability to synthesize imidazo[1,2-a]pyridine-based drug molecules such as Alpidem.

Flow chemistry synthesis of zolpidem, alpidem and other GABAA agonists and their biological evaluation through the use of in-line frontal affinity chromatography

The flow of information between chemical and biological research can present a bottleneck in pharmaceutical research. Tools that bridge these disciplines and aid information exchange have therefore clear value. Over the last few years, both synthetic chemistry and biological screening have benefited from automation, and a seamless chemistry-biology interface is now possible. We report here on the use of flow processes to perform synthesis and biological evaluation in an integrated manner. As proof of concept, a flow synthesis of a series of imidazo[1,2-a]pyridines, including zolpidem and alpidem, was developed and connected to a Frontal Affinity Chromatography screening assay to investigate their interaction with Human Serum Albumin (HSA). The Royal Society of Chemistry 2013.

Synthesis of imidazopyridines from the Morita-Baylis-Hillman acetates of nitroalkenes and convenient access to alpidem and zolpidem

A variety of functionalized imidazo[1,2-a]pyridines have been synthesized through a one-pot, room temperature, and reagent-free reaction between MBH acetates of nitroalkenes and 2-aminopyridines. The reaction involves a cascade inter-intramolecular double aza-Michael addition of 2-aminopyridines to MBH acetates. Our methodology is marked by excellent yield, regioselectivity and, above all, adaptability to synthesize imidazopyridine-based drug molecules such as Alpidem and Zolpidem.

General and efficient copper-catalyzed three-component coupling reaction towards imidazoheterocycles: One-pot synthesis of alpidem and zolpidem

(Figure Presented) Three is not a crowd: A method for the construction of Imidazopyridine, imidazoquinoline, and imidazoisoquinoline frameworks has been developed. The synthetic utility of this method was demonstrated in a highly efficient one-pot synthesis of the drugs alpidem and Zolpidem (see scheme).

Synthesis and binding affinity of 2-phenylimidazo[1,2-α]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new series of high-affinity and selective ligands for the peripheral type

A number of 6-substituted or 6,8-disubstituted alkyl 2- phenylimidazo[1,2-a]pyridine-3-carboxylates 5a-h,-acetates 5i-s, 6a-g, and - propionates 5t, 6h and of N,N-dialkyl-2-phenylimidazo[1,2-α]pyridlne-3- carboxamides 7a-d, -aceramides 7e-t or -propionamide 7u were prepared following new synthetic methods, and their affinities for both the central (CBR) and the peripheral (PBR) benzodiazepine receptors evaluated. The compounds of the ester series displayed low affinity for both receptor types. Conversely, most of N,N-dialkyl(2-phenylimidazo[1,2-a]pyridin-3-yl)acetamides 7e-t proved to possess high affinity and selectivity for CBR or PBR depending on the nature of substituents at C(6)- and/or C(8) on the heterocyclic ring system. In particular, the 6-substituted compounds 7f-n displayed ratios of IC50 values (IC50(CBR)/IC50(PBR)) ranging from 0.32 (7m) to 232 (7k), while the 6,8-disubstituted compounds 7o-t were more than 1000-fold more selective for PBR versus CBR. Compounds 7f,m were examined in several different benzodiazepine receptor subtypes. Expression of specific GABA(A) receptor subunit assemblies in Xenopus oocytes was utilized to evaluate functionally both the efficacy and potency of the positive modulation of GABA-evoked C1+ currents by 7f and 7m in comparison with Zolpidem. The rank order of potencies of these drugs was 7f (EC50 = 3.2 x 10-8 M) > Zolpidem (EC50 = 3.6 x 10-8 M) > 7m (EC50 = 2.2 x 10-7 M). The actions of these compounds were also tested on α2β2γ2(s) receptors. However, the EC50 of these compounds was increased, compared to α1β2γ2(s) receptors, by 30-, 4-, and 5-fold for 7m, 7f, and Zolpidem, respectively. Finally, these compounds were almost completely devoid of activity at receptors containing the α5 subunit.